Kornimate/medical-research-clean huggingface dataset:
aaa rupture risk assessment in covid-19 pandemic

Conditions: Abdominal Aortic Aneurysm; COVID-19

Summary: the acute phase of the covid-19 pandemic requires a redefinition of healthcare system to increase the number of available intensive care units for covid-19 patients. this leads to the postponing of elective surgeries including the treatment of abdominal aortic aneurysm (aaa). the probabilistic rupture risk index (prri) recently showed its advantage over the diameter criterion in aaa rupture risk assessment. its major improvement is in increased specificity and yet has the same sensitivity as the maximal diameter criterion. the objective of this study was to test the clinical applicability of the prri diagnostic method in a quasi-prospective observational patient cohort study.


Eligibility criteria:
inclusion criteria: * presence of asymptomatic abdominal aortic aneurysm (aaa) * regular ct angiography scans available exclusion criteria: * rupture of aaa

Keywords: abdominal aortic aneurysm biomechanics rupture risk predictability covid-19
alpha lipoic acid for burning mouth

Conditions: Burning Sore Mouth

Summary: discussion and evaluation of patients with sore and burning mouth to determine whether alpha lipoic acid is helpful in managing their symptoms.


Eligibility criteria:
patients seen in the department of dermatology with diagnosis of burning mouth syndrome between 2000 and 2005
analysis of rats, vats and open lung resections after neoadjuvant chemo-immunotherapy in patients performed in five referred centers

Conditions: Non-Small Cell Lung Cancer

Summary: the study is a retrospective observational study. the study is designed to be multicentric and international and it will analyze medical records from selected patients diagnosed with locally advanced and resectable nsclc who underwent lung resection by robotic, vats and open approach after receiving neoadjuvant chemo-immunotherapy. there are no risks for the patients, as this is a retrospective data collection.

the use of neoadjuvant chemo-immunotherapy for the treatment of non-small cell lung cancer (nsclc) is increasing. however, there is limited research comparing the feasibility and oncologic efficacy of robot-assisted thoracoscopic surgery (rats), video-assisted thoracoscopic surgery (vats), and open lung resection, in patients already treated with neoadjuvant chemo-immunotherapy. this study aims to evaluate the benefits of rats compared to vats and open surgery in terms of short-term outcomes for patients with nsclc undergoing neoadjuvant chemo-immunotherapy. all adult patients diagnosed with locally advanced and resectable nsclc who underwent lung resection from 01-01-2016 to 31-03-2024 by robotic, vats and open approach after receiving neoadjuvant chemo-immunotherapy will be included. patients are divided into three groups: robotic lung resection; video-assisted thoracoscopic (vats) lung resection; open lung resection.

Eligibility criteria:
inclusion criteria: * diagnosis of clinical or pathological stage iib (t1-2, hilar n1, m0) and iii (any t, n1-2, m0) nsclc surgically treated with robotic, vats and open approach with radical intent from 1st of january 2016 to 31st of march 2024 * received neoadjuvant chemo-immunotherapy or immunotherapy alone * age \>= 18 years old at the moment of surgery exclusion criteria: * age \<18 years old at the moment of surgery

Keywords: video-assisted thoracoscopic surgery robot-assisted thoracoscopic surgery open approach
blood biomarkers of injury and outcome in traumatic brain injury

Conditions: Traumatic Brain Injury

Summary: blood samples will be drawn on traumatic brain injury patients who are participating in the protect iii study.

blood samples will be drawn on traumatic brain injury patients who are participating in the protect iii study just prior to the initiation of the study drug infusion and 24 and 48 hours from the time they are enrolled in the study to test for biomarkers that may help predict how severe the injury is and how well they improve. the investigators will also test to see if the study medication is being absorbed and is staying at a consistent level in the blood stream.

Eligibility criteria:
inclusion criteria: * moderate to severe brain injury (igcs 12-4 or motor response 2-5 if intubated). * age \>18 years (or developmental stage tanner 5 in patients where age is not known) * blunt, traumatic, closed head injury (altered mental status due to brain injury) * able to initiate study drug infusion within 4 hours from time of injury - exclusion criteria: * non-survivable injury as determined by treating * bilateral dilated unresponsive pupils * spinal cord injury with neurological deficits, pre-injury paralysis (quad/paraplegic) * inability to perform activities of daily living (adl) without assistance * cardiopulmonary arrest * status epilepticus on arrival or concern for post ictal state * systolic blood pressure \< 90 for two consecutive readings at least 5 minutes apart any time prior to randomization * o2 sat \< 90 for at least 5 consecutive minutes any time prior to randomization * prisoner or ward of state * known active breast or reproductive organ cancers (via medical records or family interview) * known allergy to progesterone or intralipid components (egg yolk) (via medical records or family interview) * known history of blood clotting disorder (protein s or c deficiency, etc.) or history of pulmonary embolism (via medical records or family interview) or active/ongoing thromboembolic event (myocardial infarction, ischemic stroke, pulmonary embolism, deep vein thrombosis). * blood or serum ethanol (etoh) ≥ 250 mg % * positive qualitative urine or serum pregnancy test * concern for inability to follow up at 6 months (residence in foreign country, homeless with limited contacts, * undocumented immigrants, or high likelihood of becoming incarcerated during study period, etc.) * patient in opt out registry or wearing opt out bracelet -

Keywords: traumatic brain injury
mr colonography with fecal tagging. barium vs. bariumferumoxsil

Conditions: Colorectal Cancer; Polyps

Summary: the purpose of this study is to determine whether barium or bariumferumoxsil is better for fecal tagging in mr colonography. patients referred to colonoscopy are offered mr colonography before colonoscopy. two days before colonography, patients ingest either a contrast agent a (200 ml barium sulphate solution 1g/ml)) four times a day or a 200 ml contrast agent b (barium sulfate(25%) and ferumoxil(75%)) four times a day, which will render fecal masses "invisible" on the following mr colonography. the patients are randomised to either contrast agent a or b. the examinations are evaluated by two independent blinded readers, who will rate the tagging quality of the contrast agents. the quality of tagging will be rated by a visual analog scale (vas) and relative contrast (recon = iwall - ilumen/ iwall + ilumen).


Eligibility criteria:
inclusion criteria: * suspicion of colorectal polyps or cancer * referred for colonoscopy exclusion criteria: * suspicion of ibd * pacemaker * metal in the body * claustrophobia * pregnancy

Keywords: colorectal polyps colorectal cancer virtual colonoscopy fecal tagging mr colonography
a study to compare pk, pd and safety of the ad-214 10/600mg and rabeprazole

Conditions: Gastroesophageal Reflux Disease

Summary: a study to compare safety, pharmacokinetics and pharmacodynamics of ad-214 10/600mg to rabeprazole 10mg in healthy volunteers.

this study is to compare the safety, pharmacokinetic characteristics and pharmacodynamics characteristics of ad-214 10/600mg compared with administration of rabeprazole 10mg in healthy volunteers.

Eligibility criteria:
inclusion criteria: * age 19\~50 years in healthy volunteers * bmi is more than 18.0 kg/m\^2 , no more than 27.0 kg/m\^2 * subjects who have ability to comprehend the objectives, contents of study and property of study drug before participating in trial and have willingness to sign of informed consent in writing exclusion criteria: * presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study, including clinically significant disorders in digestive system, neuropsychiatric system, endocrine system, liver, cardiovascular system * subjects who judged ineligible by the investigator
the pathophysiology of bortezomib induced peripheral neuropathy

Conditions: Multiple Myeloma

Summary: since the pathophysiology of bipn still remains unclear, in the present study we are going to assess the development of bipn in newly diagnosed myeloma patients, based on clinical neurological examination and electrophysiological study (emg) and trying to find out if there is any relationship between oxidative stress generation measured by serum malonyldialdehyde - (mda) and urinary isoprostane, and the development of bipn, which can explain important part of the bipn pathophysiology and can suggest new ideas of treatment and prophylactic strategies of peripheral neuropathy.

the proteasome inhibitor bortezomib has shown impressive clinical activity alone and in combination with other novel agents for the treatment of multiple myeloma (mm). peripheral neuropathy is a significant dose limiting toxicity of bortezomib, which typically occurs within the first treatment cycles with bortezomib, reaching plateau around cycle 5, and does not appear to increase thereafter. although bortezomib is known to be selective proteasome inhibitor, the mechanisms of cytotoxicity are poorly understood. it has been theoretically hypothesized that bortezomib abrogates the degradation of i-kb, which blocks the transcriptional activity of nf-kb, however, recent studies demonstrated that bortezomib elicits activation of multiple pathways in cancer cells, such as reactive oxygen species (ros) pathway. the involvement of oxidative stress is supported by emerging studies showing that ros generation plays a critical role in the initiation of the bortezomib induced apoptotic cascade. oxidative stress is a complex and dynamic situation characterized by an imbalance between the productions of ros and the availability and action of antioxidants.

Eligibility criteria:
inclusion criteria: 1. a total of 30 newly diagnosed patients (age \> 18 years) with multiple myeloma (stage3 durie and salmon, ecog-performance status \<2), who are candidates for bortezomib therapy will be enrolled in the study (duration of the study 6 months). exclusion criteria: 1. patients with relapsed or progressive multiple myeloma. 2. performance status \> 2. 3. prior treatment with neuropathic agents such as oncovin and thalidomide.
neoadjuvant combination immunotherapy for stage iii melanoma

Conditions: Cutaneous Melanoma

Summary: determine safety and efficacy of pre-operative combination immunotherapy with talimogene laherparepvec (t-vec)/pembrolizumab given prior to complete lymph node dissection in resectable stage 3 cutaneous melanoma with clinically apparent lymph node metastases.

this is a single arm phase 2 study of pre-operative combination immunotherapy with pembrolizumab and t-vec given for 6 months prior to complete lymph node dissection for stage 3 resectable cutaneous melanoma with clinically apparent lymph node metastases.

Eligibility criteria:
inclusion criteria: * 18 years of age, any race or sex, who have pathologically confirmed cutaneous melanoma * ecog performance status of 0 or 1 * adequate hematologic, hepatic, renal and coagulation function * must have measurable disease and have an injectable target lymph node for intralesional therapy administration * primary melanoma has been resected * pathologically confirmed resectable stage iii disease, clinically apparent. resectability is at the discretion of the treating surgeon who is a melanoma specialist. * stage iii disease can be at time of diagnosis of primary melanoma or a recurrence after initial treatment of stage i-ii disease. * braf mutant or wild type allowed (mutations status not necessary for enrollment) * signed, written informed consent exclusion criteria: * cannot have metastatic (ajcc m1) disease * no primary mucosal or uveal melanoma * no evidence of melanoma associated with immunodeficiency state or history or other malignancies (other than non-melanoma skin cancer) within the past 3 years * may not have been previously treated with t-vec, any other oncolytic virus, pembrolizumab, or any other pd-1, pd-l1, or pd-l2 inhibitor * must not have a history or evidence of symptomatic autoimmune pneumonitis, glomerulonephritis, vasculitis, or other symptomatic autoimmune disease, document history of autoimmune disease or syndrome requiring systemic treatment in the past two years (i.e. use of disease modifying agents, steroids, or immunosuppressive agents) except vitiligo or resolved childhood asthma/atopy, or evidence of clinically significant immunosuppression * must not have active herpetic skin lesions or prior complications of herpetic infection and must not require intermittent or chronic treatment with an anti-herpetic drug (e.g. acyclovir) other than intermittent topical use
temporal postoperative pain signatures

Conditions: Pain, Postoperative

Summary: the purpose of this research study is to determine what causes pain after surgery to increase or decrease over time.

before surgery, study participants will be asked questions about age, gender, race/ethnicity, annual income, and education level. study participants will also be questioned regarding prior pain experiences, their mood and how they think about pain. a small test tube of blood, a cheek swab or a saliva sample will be taken to see what genetic differences may influence individuals pain after surgery. after surgery, study participants will be asked questions about their pain intensity while in the hospital. additional information will be collected about the effects of pain medicine, and their recovery from surgery. following discharge from the hospital, study participants will be contacted monthly to confirm continued communication. study participants will also be contacted six months after surgery, and asked to complete a final survey about their pain after surgery.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * anticipated length of hospital stay of 72 hours or greater * expected post-operative survival greater than 6 months exclusion criteria: * \< 18 years of age * anticipated need for prolonged post-operative intubation (greater than 24 hours) * urgent or emergent surgical procedure * inability to understand or participate in questionnaires, surveys or data collection

Keywords: postoperative pain surgery pain resolution pain intensity persistent postsurgical pain pain-related genes analgesic
gut derived hormones, body composition and metabolism in prader-willi syndrome

Conditions: Prader-Willi Syndrome

Summary: the purpose of this study is to investigate the effects of a glp-1 agonist on satiety hormones in patients with prader-willi syndrome (genetic defect causing obesity).

prader-willi syndrome (pws) is the most frequent known genetic disorder of obesity. hyperphagia is the main barrier to independent living in adults with pws, and hitherto behavioural restraints and environmental modification are the only effective management measure. the emerging costs for professional care are immense. thus, there is an urgent need for treatment which reduce appetite and food intake in this patient group. agonists of the gut derived hormone glp-1 which reduces food intake and causes weight loss due to slowed gastric emptying and through direct central effects. the aim of this pilot drug trial is to analyse the effect of a glp-1 agonist on appetite regulating hormones, insulin secretion and energy expenditure before and after a meal.

Eligibility criteria:
inclusion criteria: * see below exclusion criteria: * diabetes mellitus, acute infections
sarcopenia in chronic lung diseases

Conditions: Sarcopenia; COPD; Asthma; ILD

Summary: inclusion criteria a)outpatients with copd (chronic obstructive pulmonary disease) or ild (interstitial lung disease) from department of chest medicine in taichung veterans general hospital, judged by the doctor that they do not need hospitalization or emergent treatment. b) patients who agree to provide the id card number to the research team for usage as a link to the national health insurance research database and health bank to explore the continuity of care and the use of medical resources

this study is a prospective, multi-center, and non-invasive cohort study. all participants are diagnosed with asthma, copd and ild. we use sarc-calf questionnaire, frailty questionnaire and grip strength as a tool for prescreen. according to the 2019 asian sarcopenia consensus, participants are examined by sarc-calf questionnaire, grip strength test and a physical performance test, including sit-stand test, short physical performance battery (sppb), gait speed test and six-minute walk test. bioelectrical impedance analysis (bia) and dual-energy x-ray absorptiometry (dxa) are applied to all participants by to analyze body composition. participants are further classified into no sarcopenia group, sarcopenia group, and severe sarcopenia group to derive the prevalence.

Eligibility criteria:
inclusion criteria: 1. outpatients with copd (chronic obstructive pulmonary disease) or ild (interstitial lung disease) from department of chest medicine in taichung veterans general hospital, judged by the doctor that they do not need hospitalization or emergent treatment. 2. those who meet the conditions for frailty diagnosis after assessment by the frailty scale 3. patients who agree to provide the id card number to the research team for usage as a link to the national health insurance research database and health bank to explore the continuity of care and the use of medical resources 4. age\>=20 exclusion criteria: 1. patients who refuse to sign the consent form 2. patients who are bed ridden or unable to walk due to physical disabilities 3. patients with terminal cancer or human acquired immunodeficiency syndrome 4. patients with edema (pitting edema +2)
clinical validation of new commercial sleep monitoring devices

Conditions: Sleep Apnea

Summary: this study seeks to validate three new commercial sleep monitoring devices: fitbit, jawbone up, and microsoft band by comparison against concurrent polysomnography (psg), which is considered the gold standard for sleep assessment. this research is being done because if proven to accurately analyze sleep,these devices may make conducting in-home sleep studies easier and more affordable in the future.

this study seeks to validate three new commercial sleep monitoring devices: fitbit, jawbone up, and microsoft band by comparison against concurrent polysomnography (psg), considered the gold standard assessment for sleep physiology. the investigators emphasize here that the commercial sleep monitoring devices (fitbit, jawbone up, and microsoft band) are used in addition to psg and not in place of it. subjects will be recruited from those patients attending a regularly scheduled overnight psg sleep study at the weill cornell medical college center for sleep medicine. willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non-dominant hand when prepared for the sleep study by a technician. subjects willing to wear more than one sleep monitoring device may be fitted with two different sleep monitoring devices, e.g., a fitbit and a jawbone up or a fitbit and a microsoft band. sleep monitoring device(s) will be removed from the subject's wrist in the morning at the conclusion of the sleep study. data will be transferred from the sleep monitoring device(s) for later statistical analysis and comparison with scored polysomnogram. device(s) will be cleaned (using antiseptic wipes), reset,recharged, and otherwise prepared for reuse.

Eligibility criteria:
inclusion criteria: * attending a regularly scheduled overnight polysomnography (psg) sleep study at the weill cornell medical college center for sleep medicine. exclusion criteria: * not attending a regularly scheduled overnight polysomnography (psg) sleep study at the weill cornell medical college center for sleep medicine. * under 18 or over 80 years old. * pregnancy * unable to provide informed consent.

Keywords: in lab sleep studies
a study to characterize the safety, pk and biological activity of cc-930 in idiopathic pulmonary fibrosis (ipf)

Conditions: Idiopathic Pulmonary Fibrosis; Pulmonary Fibrosis; Fibrosis; Interstitial Lung Disease; Lung Diseases, Interstitial

Summary: the primary purpose of the study is to evaluate the safety and pk profile of cc-930 in idiopathic pulmonary fibrosis patients.


Eligibility criteria:
inclusion criteria: * males and females of non-childbearing potential ≥50 years of age (at the time of signing the informed consent document) with documented ipf * diagnosis of ipf based on current ats/ers guidelines * usual interstitial pneumonia (uip) pattern on hrct and/or uip pattern on histopathology (ie surgical lung biopsy), and * exclusion of known causes of interstitial lung disease (such as environmental exposure, connective tissue disease and drug toxicity), or * uip pattern on surgical lung biopsy required if hrct is inconsistent with uip exclusion criteria: * fvc : \ 90% predicted * dlco:\ 90% predicted * saturated oxygen (spo2) of \<92% (room air \[sea level\] at rest). spo2 of \< 88% (room air \[≥ 5,000 feet above sea level (1524 meters\]) at rest) * use of any cytotoxic/immunosuppressive agent (other than prednisone ≤ 12.5 mg/day or equivalent) including, but not limited to, azathioprine, cyclophosphamide, methotrexate and cyclosporine within 4 weeks of screening * use of any cytokine modulators: * use of any biologic agent (such as etanercept, adalimumab, efalizumab, infliximab, golimumab, certolizumab) within 12 weeks or five half-lives of screening, and in the case of rituximab, use within 24 weeks of screening or no recovery of cd 19-positive b lymphocytes if the last dose of rituximab has been more than 24 weeks prior to screening * alefacept within 24 months of randomization * use of any therapy targeted to treat ipf (including but not limited to d-penicillamine, endothelium receptor antagonist \[eg bosentan, ambrisentan\], interferon gamma-1b, pirfenidone) within 4 weeks of screening * use of n-acetylcysteine (nac) for ipf (≥1800 mg/day) within 4 weeks of screening * use of any investigational drug within one month of screening, or 5 pd/pk half lives, if known (whichever is longer) * current smoker

Keywords: idiopathic pulmonary fibrosis pulmonary fibrosis fibrosis interstitial lung disease lung diseases, interstitial cc-930